Travere Therapeutics/$TVTX
14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Ticker
$TVTX
Sector
Primary listing
Employees
497
Headquarters
Website
TVTX Metrics
BasicAdvanced
$2.6B
-
-$0.29
0.81
-
Price and volume
Market cap
$2.6B
Beta
0.81
52-week high
$42.13
52-week low
$12.91
Average daily volume
1.6M
Financial strength
Current ratio
2.736
Quick ratio
2.528
Long term debt to equity
281.167
Total debt to equity
286.283
Interest coverage (TTM)
-5.85%
Profitability
EBITDA (TTM)
-2.081
Gross margin (TTM)
55.91%
Net profit margin (TTM)
-5.21%
Operating margin (TTM)
-12.80%
Effective tax rate (TTM)
-2.01%
Revenue per employee (TTM)
$990,000
Management effectiveness
Return on assets (TTM)
-6.55%
Return on equity (TTM)
-57.80%
Valuation
Price to revenue (TTM)
5.123
Price to book
22.31
Price to tangible book (TTM)
2,669.07
Price to free cash flow (TTM)
-123.398
Free cash flow yield (TTM)
-0.81%
Free cash flow per share (TTM)
-0.228
Growth
Revenue change (TTM)
110.45%
Earnings per share change (TTM)
-92.97%
3-year revenue growth (CAGR)
64.89%
10-year revenue growth (CAGR)
17.25%
3-year earnings per share growth (CAGR)
-59.68%
10-year earnings per share growth (CAGR)
-21.37%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
TVTX News
AllArticlesVideos
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Business Wire·3 weeks ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 weeks ago
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Travere Therapeutics stock?
Travere Therapeutics (TVTX) has a market cap of $2.6B as of March 05, 2026.
What is the P/E ratio for Travere Therapeutics stock?
The price to earnings (P/E) ratio for Travere Therapeutics (TVTX) stock is 0 as of March 05, 2026.
Does Travere Therapeutics stock pay dividends?
No, Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders as of March 05, 2026.
When is the next Travere Therapeutics dividend payment date?
Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Travere Therapeutics?
Travere Therapeutics (TVTX) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.